Walter Newman - Leap Therapeutics Research Fellow
| LPTX Stock | USD 2.52 0.03 1.18% |
Insider
Walter Newman is Research Fellow of Leap Therapeutics
| Age | 78 |
| Address | 47 Thorndike Street, Cambridge, MA, United States, 02141 |
| Phone | 617 714 0360 |
| Web | https://www.leaptx.com |
Leap Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.4562) % which means that it has lost $0.4562 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8054) %, meaning that it created substantial loss on money invested by shareholders. Leap Therapeutics' management efficiency ratios could be used to measure how well Leap Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.17 in 2024. Return On Capital Employed is likely to rise to -1.37 in 2024. At this time, Leap Therapeutics' Non Current Assets Total are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 1.3 M in 2024, whereas Total Assets are likely to drop slightly above 45.2 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| Christine CPA | Mereo BioPharma Group | 43 | |
| Marine Popoff | Hookipa Pharma | N/A | |
| Mary DiBiase | X4 Pharmaceuticals | 63 | |
| Prof MD | Hookipa Pharma | 80 | |
| Klaus Orlinger | Hookipa Pharma | 46 | |
| Russell MS | Acumen Pharmaceuticals | 65 | |
| Lauren MD | PDS Biotechnology Corp | 64 | |
| Jackie Parkin | Mereo BioPharma Group | 66 | |
| MSc MBA | Inozyme Pharma | 52 | |
| MA MS | Inozyme Pharma | N/A | |
| PharmD Chiodin | Day One Biopharmaceuticals | N/A | |
| Jaa Roberson | Day One Biopharmaceuticals | N/A | |
| MBBS MD | Mereo BioPharma Group | 54 | |
| Daren Ure | Hepion Pharmaceuticals | N/A | |
| Stefan Riley | Inozyme Pharma | N/A | |
| Nathalie Riebel | PDS Biotechnology Corp | N/A | |
| Janice Hitchcock | Acumen Pharmaceuticals | N/A | |
| Julie MBA | Day One Biopharmaceuticals | 42 | |
| Liean MS | Acumen Pharmaceuticals | N/A | |
| BSc BSc | Hepion Pharmaceuticals | 66 | |
| Julie Bockenstette | Acumen Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.81 | ||||
| Return On Asset | -0.46 |
Leap Therapeutics Leadership Team
Elected by the shareholders, the Leap Therapeutics' board of directors comprises two types of representatives: Leap Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Leap. The board's role is to monitor Leap Therapeutics' management team and ensure that shareholders' interests are well served. Leap Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Leap Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Augustine Lawlor, Chief Officer | ||
| Cynthia MD, Chief Officer | ||
| Christine Granfield, VP Quality | ||
| Mark OMahony, Chief Officer | ||
| Jason Baum, Chief Officer | ||
| Douglas JD, General CFO | ||
| Cynthia Sirard, Chief Officer | ||
| Walter Newman, Research Fellow |
Leap Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Leap Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.81 | ||||
| Return On Asset | -0.46 | ||||
| Current Valuation | 34.11 M | ||||
| Shares Outstanding | 38.32 M | ||||
| Shares Owned By Insiders | 17.28 % | ||||
| Shares Owned By Institutions | 40.30 % | ||||
| Number Of Shares Shorted | 1.01 M | ||||
| Price To Earning | (1.85) X | ||||
| Price To Book | 1.97 X | ||||
| Price To Sales | 160.10 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Leap Stock Analysis
When running Leap Therapeutics' price analysis, check to measure Leap Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Leap Therapeutics is operating at the current time. Most of Leap Therapeutics' value examination focuses on studying past and present price action to predict the probability of Leap Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Leap Therapeutics' price. Additionally, you may evaluate how the addition of Leap Therapeutics to your portfolios can decrease your overall portfolio volatility.